Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;207(6):812-820.
doi: 10.1016/j.banm.2023.01.029. Epub 2023 Apr 25.

[Post-COVID-19 syndrome]

[Article in French]
Affiliations
Review

[Post-COVID-19 syndrome]

[Article in French]
David Montani et al. Bull Acad Natl Med. 2023 Jun.

Abstract

In the aftermath of acute infection with the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), a large number of symptoms persist or appear, constituting a real syndrome called "long COVID-19" or "post-COVID- 19" or "post-acute COVID-19 syndrome". Its incidence is very high, half of patients showing at least one symptom at 4-6 months after Coronarovirus infectious disease 2019 (COVID-19). They can affect many organs. The most common symptom is persistent fatigue, similar to that seen after other viral infections. Radiological pulmonary sequelae are relatively rare and not extensive. On the other hand, functional respiratory symptoms, primarily dyspnoea, are much more frequent. Dysfunctional breathing is a significant cause of dyspnoea. Cognitive disorders and psychological symptoms are also very common, with anxiety, depression and post-traumatic stress symptoms being widely described. On the other hand, cardiac, endocrine, cutaneous, digestive or renal sequelae are rarer. The symptoms generally improve after several months, even if their prevalence at two years remains significant. Most of the symptoms are favored by the severity of the initial illness, and the psychic symptoms by the female sex. The pathophysiology of most symptoms is poorly understood. The influence of the treatments used in the acute phase is also important. Vaccination, on the other hand, seems to reduce their incidence. The sheer number of affected patients makes long-term COVID-19 syndrome a public health challenge.

Dans les suites de l’infection aiguë par le severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), de très nombreux symptômes persistent ou apparaissent, constituant un véritable syndrome appelé « COVID-19 long » ou « syndrome post-COVID-19 » ou « syndrome de COVID-19 post-aigu ». Son incidence est très élevée, la moitié des patients présentant au moins un symptôme à 4–6 mois après le Coronarovirus infectious disease 2019 (COVID-19). Ils peuvent toucher de très nombreux organes. Le symptôme le plus fréquent est une fatigue persistante, semblable à celle rencontrée après d’autres infections virales. Les séquelles pulmonaires radiologiques sont relativement rares et peu étendues. En revanche, les symptômes respiratoires fonctionnels, en premier lieu la dyspnée, sont beaucoup plus fréquents. La respiration dysfonctionnelle est une cause de dyspnée non négligeable. Des troubles cognitifs et des symptômes psychiques sont aussi très fréquents, les symptômes anxieux, dépressifs et de stress post-traumatique étant largement décrits. Les séquelles cardiaques, endocriniennes, cutanées, digestives ou rénales sont en revanche plus rares. Les symptômes vont globalement en s’améliorant au terme de plusieurs mois, même si leur prévalence à deux ans reste non négligeable. La plupart des symptômes sont favorisés par la gravité de la maladie initiale, et les symptômes psychiques par le sexe féminin. La physiopathologie de la plupart des symptômes est mal connue. L’influence des traitements utilisés à la phase aiguë l’est aussi. La vaccination semble en revanche réduire leur incidence. Le nombre total de patients touchés fait du syndrome de COVID-19 long un défi pour la santé publique.

Keywords: Anxiety; Coronavirus infections; Depression; Dyspnea; Long-term adverse effects; Pulmonary fibrosis; SARS virus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Résumé des différents symptômes constituant le syndrome de COVID-19 long, regroupés par organes et systèmes. D’après , avec permission.

References

    1. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020 Dec 18. (NICE Guideline, No. 188.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK567261/National Institute for Health Care Excellence COVID-19 rapid guideline: managing the long-term effects of COVID-19. London; 2020.
    1. Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., Condition WHOCCDWGoP-C- A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102–e107. - PMC - PubMed
    1. Writing Committee for the CSG, Morin L., Savale L., Pham T., Colle R., Figueiredo S., et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA. 2021;325:1525–1534. - PMC - PubMed
    1. Routen A., O’Mahoney L., Ayoubkhani D., Banerjee A., Brightling C., Calvert M., et al. Understanding and tracking the impact of long COVID in the United Kingdom. Nat Med. 2022;28:11–15. - PubMed
    1. Evans R.A., McAuley H., Harrison E.M., Shikotra A., Singapuri A., Sereno M., et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9:1275–1287. - PMC - PubMed

LinkOut - more resources